Monitor and track your COPD and asthma using your smartphone

The Global Asthma Report 2018 estimates that asthma affects around 339 million people globally, while The Global Burden of Disease Study reports that there were 251 million cases of chronic obstructive pulmonary disease (COPD) in 2016. Asthma and COPD cannot be cured; however appropriate management can help relieve symptoms, improve quality of life and reduce the risk of death.

ResApp has developed smartphone-based machine learning algorithms that have been found in a prospective clinical study to accurately identify acute exacerbations in patients with asthma or COPD. ResApp also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function.

Read our press release

Scientific Presentations & Publications

Porter P, Claxton S, Wood J, Peltonen V, Brisbane J, Purdie F, Smith C, Bear N, Abeyratne U, Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Using a Smartphone-Based, Cough Centred Algorithm, ERS 2019, October 1, 2019.

Sharan RV, Abeyratne UR, Swarnkar VR, Claxton S, Hukins C, Porter P, Predicting spirometry readings using cough sound features and regression, Physiological Measurement 39(9), 2018.

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 12, 100 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.